Aralez Pharmaceuticals Inc. (ARLZ) Stock Price Up 4.7%
Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ)’s share price rose 4.7% on Monday . The company traded as high as $4.09 and last traded at $4.03, with a volume of 316,803 shares trading hands. The stock had previously closed at $3.85.
The company’s market capitalization is $272.72 million. The firm’s 50-day moving average price is $3.58 and its 200-day moving average price is $4.31.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last released its quarterly earnings data on Tuesday, August 9th. The company reported ($0.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by $0.08. The business had revenue of $12.60 million for the quarter, compared to analysts’ expectations of $9.70 million. Aralez Pharmaceuticals’s revenue was up 142.3% compared to the same quarter last year. Equities research analysts expect that Aralez Pharmaceuticals Inc. will post ($1.00) earnings per share for the current fiscal year.
In other news, insider Eric Trachtenberg bought 10,000 shares of the company’s stock in a transaction dated Monday, May 16th. The stock was bought at an average price of $3.76 per share, with a total value of $37,600.00. Following the completion of the acquisition, the insider now owns 144,500 shares of the company’s stock, valued at $543,320. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Andrew I. Koven bought 71,500 shares of the company’s stock in a transaction dated Thursday, May 12th. The shares were purchased at an average cost of $3.49 per share, with a total value of $249,535.00. Following the acquisition, the insider now directly owns 1,610,306 shares of the company’s stock, valued at approximately $5,619,967.94. The disclosure for this purchase can be found here.
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.